PS

Excited to have presented our work on #HER2 mutations in #NSCLC at the #TTLC24 meeting in Santa Monica. #LCSM @IASLC @politikaterina @MJGrantMD @TalalZarif1 @Science_Jake @DrRoyHerbstYale @SmilowCancer

ADC’s Bystander Effect may be crucial for efficacy! In a provocative recent paper, HER2 ADC’s payload may not need ADC internalization for efficacy ! Activity may rely on extracellular proteases, such as cathepsin L (CTSL). This extracellular release in the TME appears to kill…

Another ALK inhibitor (#ensartinib) gets @US_FDA approval eXalt3 study: - 1L, Ph III, ALK+ mNSCLC vs Crizotinib - Ensartinib vs crizotinib (NR vs 12.7mos, HR: 0.45) - CNS ORR 64% w/ ensartinib vs 21% - AES: rash, 💪 pain, nause #OncTwitter #MedTwitter @OncoAlert

Great posters at #HTTR24 from fellows Drs. @StockhammerPaul and Brinda Gupta exploring aspects of #EGFR NSCLC resistance such as role of tumor suppressors and the expression of #SEZ6 in SCLC transformation. And both are alumni of the @EGFRSummit!

📖 👉New online: @NaturePortfolio Review Clinical Oncology. 2024 marks the 20th anniversary of the discovery of #EGFR in #NSCLC. rdcu.be/d1V2Q Osimertinib represents just one of many significant advancements, as a community @IASLC, we have: 1. Over 10 approved…

A must-read Review on the ever-evolving field of #EGFR mut #NSCLC in@NatRevClinOncol highlighting: ➡️Strategies to improve on 1L 3rd Gen TKI mono therapy ➡️ Ways to tackle resistance post-Osi ➡️Perioperative landscape @LeXiuning @danieltanmd @RamalingamMD @IASLC #LCSM #some

2/2 🫁 Stage III - Unresectable NSCLC 🫁 🌟 Treatment algorithm 🌟 Chemoradiation therapies 🌟 Consolidation therapies

Slide updated ✅ @OncBrothers @OncoAlert #lcsm

Why Yale? A Thread by our Program Director Dr. Siegel @MarkDSiegel1 We are sharing the whole letter here to make sure all our applicants will get a chance to read it. 🧵🧵

Our goal is to help early career investigators foster collaborations early in their careers and support their important work. YOU are our future. Please share with early investigators you know! Submit your abstract for the #EGFRSummit Don’t miss the the 9/30 deadline!…

Highly recommended program for fellows and early-career. I met some of the best colleagues and #mentors in #lcsm @lungoncdoc @Joshua_Reuss @StockhammerPaul @StephenVLiu @jillfeldman4 @LeciaSequist

It is not quite 2 months since our first year fellows started fellowship and what a brilliant group it is. Case and point is Dr. Casasanta who excelled on one of our toughest services, hematology consults with her attending stating "Nicole is a rockstar." Oh we know 💫🤟!

It might take us a second to coordinate getting a group picture, but it's because we just like each other. And we certainly love our first year fellows class! It was a joy learning about each of you at the Heme-Onc Fellows Welcome Party. You already make our family richer. 💙

Day made thanks to @ASCOTECAG @ASCO for providing a platform for young trainees at #ASCO24 as we presented our work from @YaleIMed @YaleCancer @StockhammerPaul @MJGrantMD! @FernandoDiazMD1 @jacobadashek

Finally, our long-awaited first year fellows are here! We are so excited to add this crew to our family and can not wait to watch them all shine! Let's go class of 2027!

Check out our Resource paper published today in @CellReports @CellPressNews on the epigenetic features of sarcomatoid RCC! Effort led with co-first @KarlSemaan with great mentorship from @SylvanBacaLab #MattFreedman @DrChoueiri and co-authors! Link: cell.com/cell-reports/f…

Why do some patients benefit less than others from precision cancer medicine? We are excited to share our paper "Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling” out in @NatureComms. nature.com/articles/s4146… 🧵

Calling for #HTTR24 abstracts that dive deep into the mechanisms, biomarkers, & models that drive our understanding & treatment of drug tolerance & resistance in #NSCLC. Share your groundbreaking research & contribute to the future of #lungcancer therapy. bit.ly/HTTR24AS

Dana-Farber in the wild: Marc Machaalani, MD, (@MarcMachaalani) of the Lank Center (@DanaFarber_GU) presents data on the prevalence of ERBB2 mutations in urothelial carcinoma. #ASCO24

In case you missed it, #ASCO24 is officially rebranded as #ASCOLung 😂 Especially because this amazing human @jillfeldman4 was awarded patient advocate of the year! We love you so much!! 🤍 @ASCO @FawziAbuRous @LungCancerRx

Enjoyed sharing our work on ERBB2 mutations in Lung Cancer with a Merit Award from @ConquerCancerFd! Thanks to @StockhammerPaul for spearheading this effort, @MJGrantMD @politikaterina #SarahGoldberg for the immense mentorship and to @TradIMYale for their support! #ASCO24